Talthera Appoints New CMO, Elects Director
Ticker: TLPH · Form: 8-K · Filed: Mar 1, 2024 · CIK: 1427925
| Field | Detail |
|---|---|
| Company | Talphera, Inc. (TLPH) |
| Form Type | 8-K |
| Filed Date | Mar 1, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, board-election, corporate-governance
Related Tickers: ACRX
TL;DR
Talthera (formerly AcelRx) just named a new CMO and added a director to the board.
AI Summary
Talthera, Inc. announced on February 26, 2024, the appointment of Dr. Jonathan F. Miller as Chief Medical Officer and the election of Ms. Sarah E. Empey to its Board of Directors. The company also reported on compensatory arrangements for its officers. Talthera, Inc. was formerly known as AcelRx Pharmaceuticals Inc. and is incorporated in Delaware.
Why It Matters
Changes in key leadership roles like Chief Medical Officer and Board of Directors can signal strategic shifts or new directions for a pharmaceutical company's development pipeline.
Risk Assessment
Risk Level: low — This filing primarily concerns executive appointments and board changes, which are routine corporate governance events.
Key Players & Entities
- Talthera, Inc. (company) — Registrant
- Jonathan F. Miller (person) — Appointed Chief Medical Officer
- Sarah E. Empey (person) — Elected to Board of Directors
- AcelRx Pharmaceuticals Inc. (company) — Former company name
- February 26, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer of Talthera, Inc.?
Dr. Jonathan F. Miller has been appointed as the new Chief Medical Officer of Talthera, Inc.
Who was elected to the Board of Directors of Talthera, Inc.?
Ms. Sarah E. Empey was elected to the Board of Directors of Talthera, Inc.
What was Talthera, Inc.'s former name?
Talthera, Inc.'s former name was AcelRx Pharmaceuticals Inc.
On what date was this Form 8-K filed?
This Form 8-K was filed on March 1, 2024.
In which state is Talthera, Inc. incorporated?
Talthera, Inc. is incorporated in Delaware.
Filing Stats: 732 words · 3 min read · ~2 pages · Grade level 9.6 · Accepted 2024-03-01 07:35:13
Key Financial Figures
- $0.001 — ge on which registered Common Stock , $0.001 par value TLPH The Nasdaq Global Mar
- $1.00 — a minimum closing bid price of at least $1.00 per share (the "Minimum Bid Requirement
Filing Documents
- acrx20240229_8k.htm (8-K) — 30KB
- ex_632981.htm (EX-99.1) — 13KB
- ex_632981img001.jpg (GRAPHIC) — 4KB
- 0001437749-24-006219.txt ( ) — 184KB
- tlph-20240226.xsd (EX-101.SCH) — 3KB
- tlph-20240226_def.xml (EX-101.DEF) — 11KB
- tlph-20240226_lab.xml (EX-101.LAB) — 15KB
- tlph-20240226_pre.xml (EX-101.PRE) — 11KB
- acrx20240229_8k_htm.xml (XML) — 3KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignations of Directors On February 26, 2024, Richard Afable, M.D. and Howard B. Rosen resigned as members of the board of directors of Talphera, Inc. (the "Company"), and any and all committees thereof, effective immediately. At the time of their resignations, Dr. Afable served on the Compensation Committee and Mr. Rosen served on the Audit Committee. Dr. Afable and Mr. Rosen's resignations were not due to any disagreement with the Company on any matter relating to its operations, policies or practices. On February 28, 2024, Pamela P. Palmer, M.D., Ph.D. resigned as a member of the Company's board of directors effective immediately. Dr. Palmer will remain as the Company's Chief Medical Officer. Dr. Palmer's resignation was not due to any disagreement with the Company on any matter relating to its operations, policies or practices. Following the above resignations, the board of directors reconstituted the committees of the board of directors as follows: Audit Committee Jill Broadfoot (Chair) Marina Bozilenko Stephen J. Hoffman, M.D., Ph.D. Compensation Committee Mark Wan (Chair) Stephen J. Hoffman, M.D., Ph.D. Abhinav Jain Financing and Strategic Transactions Committee Marina Bozilenko (Chair) Adrian Adams Abhinav Jain Mark Wan Nominating and Corporate Governance Committee Adrian Adams (Chair) Abhinav Jain Mark Wan
01
Item 8.01 Other Events. On February 27, 2024, the Company received a letter from The Nasdaq Stock Market notifying the Company that it had regained compliance with Listing Rule 5450(a)(1), which requires that listed securities maintain a minimum closing bid price of at least $1.00 per share (the "Minimum Bid Requirement"). The Company regained compliance with the Minimum Bid Requirement as of February 26, 2024. The Company had previously been notified of its non-compliance with the Minimum Bid Requirement on October 18, 2023, as described in the Company's Current Report on Form 8-K filed on October 20, 2023. On March 1, 2024, the Company issued a press release announcing the reduction in the size of its board of directors from ten to seven members. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No . Description 99.1 Press Release dated March 1, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 1, 2024 TALPHERA, INC. By: /s/ Raffi Asadorian Raffi Asadorian Chief Financial Officer